{"id":"targeted-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":{"setId":"198c7caf-576b-1466-e063-6394a90afe25","title":"RENEW INTENSIVE SKIN THERAPY TARGETED ECZEMA TREATMENT (COLLOIDAL OATMEAL) CREAM [MELALEUCA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Targeted therapies work by identifying and inhibiting specific genetic mutations, signaling pathways, or proteins that drive cancer growth. Unlike conventional chemotherapy, which broadly damages rapidly dividing cells, targeted therapies exploit unique vulnerabilities in cancer cells—such as overactive growth factor receptors, constitutively active kinases, or fusion proteins—to achieve selectivity. This approach typically results in improved efficacy and reduced toxicity compared to non-selective cytotoxic agents.","oneSentence":"Targeted therapy refers to drugs designed to attack specific molecular features of cancer cells, such as mutations or overexpressed proteins, while sparing normal cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:49:19.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific indications depend on the particular targeted agent)"}]},"trialDetails":[{"nctId":"NCT07135232","phase":"NA","title":"The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2026-03-01","conditions":"Perimenopause, Menopause","enrollment":72},{"nctId":"NCT05657873","phase":"PHASE2","title":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-09","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma","enrollment":68},{"nctId":"NCT04439201","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-31","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT07496073","phase":"PHASE1","title":"A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-20","conditions":"Brain (Nervous System) Cancers","enrollment":30},{"nctId":"NCT07498400","phase":"NA","title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-01","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer","enrollment":216},{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT06985056","phase":"NA","title":"Reducing Symptom Burden Through Physical Exercise in Melanoma Patients","status":"RECRUITING","sponsor":"Universität Duisburg-Essen","startDate":"2025-08-18","conditions":"Malignant Melanoma","enrollment":104},{"nctId":"NCT07399496","phase":"NA","title":"Accelerated TMS for Apathy in PD","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-06-01","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT04439357","phase":"PHASE2","title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-25","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":4},{"nctId":"NCT07281638","phase":"NA","title":"Bedside Bike Early Mobilization Program for Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-07-05","conditions":"Immobility Syndrome, Deep Venous Thrombosis, Delirium","enrollment":80},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT04261855","phase":"PHASE1, PHASE2","title":"Targeted Therapy and Avelumab in Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-08","conditions":"Metastatic Merkel Cell Carcinoma","enrollment":19},{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT07495397","phase":"NA","title":"Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-11-01","conditions":"Epithelial Ovarian Cancer","enrollment":98},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT06400238","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-15","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT07497841","phase":"NA","title":"Development and Validation of a KAP Questionnaire for Secondary Hypertension: Evaluating a Community Short-Video Intervention in Rural Beijing","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2025-12-01","conditions":"Secondary Hypertension","enrollment":1062},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT07498933","phase":"","title":"FAP-targeted PET/NIR in Lung Malignant Tumors","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-06-03","conditions":"Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy","enrollment":200},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":"Platinum-resistant Ovarian Cancer","enrollment":18},{"nctId":"NCT07293676","phase":"NA","title":"IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2026-01-05","conditions":"Vibration, Lumbar Disc Herniation, Soft Tissue Mobilization","enrollment":45},{"nctId":"NCT07498985","phase":"NA","title":"Exercise for the Treatment of Cancer-Related Sarcopenia","status":"NOT_YET_RECRUITING","sponsor":"State University of Londrina","startDate":"2026-04-01","conditions":"Cancer, Sarcopenia","enrollment":78},{"nctId":"NCT06308822","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT05859347","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-05-15","conditions":"Cannabis Use Disorder","enrollment":46},{"nctId":"NCT02243592","phase":"","title":"Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-24","conditions":"Malignant Neoplasm","enrollment":170},{"nctId":"NCT06351371","phase":"PHASE2","title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-03","conditions":"Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT07498179","phase":"NA","title":"Intervention Programme for Seniors","status":"ENROLLING_BY_INVITATION","sponsor":"Diana Ďuricová","startDate":"2026-04-20","conditions":"Healthy","enrollment":200},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT07496099","phase":"NA","title":"Effects of Post-Isometric Relaxation and Myofascial Release on Low Back Pain With Lower Cross Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Karachi","startDate":"2026-03-25","conditions":"Low Back Pain, Mechanical, Lower Cross Syndrome, Hamstring Muscle Tightness","enrollment":60},{"nctId":"NCT07218029","phase":"PHASE3","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":815},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT07495579","phase":"PHASE2","title":"Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":146},{"nctId":"NCT03109288","phase":"PHASE1, PHASE2","title":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-11","conditions":"Multiple Sclerosis","enrollment":250},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT07495566","phase":"","title":"Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-12-30","conditions":"Inflammatory Response, Radiculopathy, Radiculopathy Lumbar","enrollment":264},{"nctId":"NCT07495137","phase":"NA","title":"The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2026-03-31","conditions":"Endoscopic Submucosal Dissection, Endoscopic Submucosal Dissection (ESD)","enrollment":160},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT07431151","phase":"NA","title":"Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients","status":"RECRUITING","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2026-02-01","conditions":"Stroke","enrollment":48},{"nctId":"NCT07497191","phase":"","title":"AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2026-03-05","conditions":"Breast Cancer, Perimenopause, Ovarian Reserve","enrollment":300},{"nctId":"NCT07495410","phase":"NA","title":"Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT","status":"ENROLLING_BY_INVITATION","sponsor":"General University Hospital, Prague","startDate":"2025-10-06","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT05691517","phase":"PHASE1","title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-12","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT01187368","phase":"NA","title":"Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System","status":"SUSPENDED","sponsor":"Evaheart, Inc.","startDate":"2020-03-31","conditions":"Heart Failure","enrollment":399},{"nctId":"NCT05554328","phase":"PHASE2","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-25","conditions":"Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":165},{"nctId":"NCT04167969","phase":"PHASE1","title":"The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-17","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT04439331","phase":"PHASE2","title":"Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT07254806","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease","status":"RECRUITING","sponsor":"DiscGenics, Inc.","startDate":"2025-12-23","conditions":"Degenerative Disc Disease","enrollment":162},{"nctId":"NCT07498907","phase":"PHASE2","title":"Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2026-05-01","conditions":"Upper Tract Urothelial Carcinoma","enrollment":192},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT04615988","phase":"","title":"Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-06-09","conditions":"Thyroid, PD-1, Cancer","enrollment":17},{"nctId":"NCT05674240","phase":"","title":"Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2022-12-06","conditions":"Cancer Pain, Chronic Pain, Cancer Associated Pain","enrollment":30},{"nctId":"NCT06921317","phase":"PHASE1, PHASE2","title":"GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma","status":"RECRUITING","sponsor":"IVIEW Therapeutics Inc.","startDate":"2025-11-19","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":12},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer","enrollment":340},{"nctId":"NCT04407767","phase":"NA","title":"A Case Formulation Approach to Cognitive Processing Therapy","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-03-15","conditions":"Posttraumatic Stress Disorder","enrollment":179},{"nctId":"NCT06303167","phase":"PHASE2","title":"Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-08","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":19},{"nctId":"NCT05727930","phase":"NA","title":"Variable Intensive Early Walking Post-Stroke - 2 (VIEWS-2)","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-01-11","conditions":"Stroke","enrollment":100},{"nctId":"NCT05454566","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.","status":"NOT_YET_RECRUITING","sponsor":"ICM Co. Ltd.","startDate":"2026-11-15","conditions":"Osteoarthritis, Knee","enrollment":18},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT06390839","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-22","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":43},{"nctId":"NCT07498777","phase":"NA","title":"Individual Alpha Frequency-Based rTMS for Post-Stroke Motor Recovery: Efficacy and Neurophysiological Mechanisms","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-04-01","conditions":"Ischemic Stroke","enrollment":34},{"nctId":"NCT06390826","phase":"PHASE2","title":"Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-01","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":10},{"nctId":"NCT04541030","phase":"","title":"Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-02","conditions":"Prostate Cancer","enrollment":241},{"nctId":"NCT04439318","phase":"PHASE2","title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-25","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":50},{"nctId":"NCT07340554","phase":"NA","title":"Neuroimaging of Adolescent Cannabis Use Treatment","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-04","conditions":"Cannabis Use, Cannabis Dependence, Cannabis Use Disorder","enrollment":80},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT04826341","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-20","conditions":"HRD Cancer, SCLC, Advanced Solid Tumors","enrollment":120},{"nctId":"NCT06360588","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-08","conditions":"Malignant Solid Neoplasm","enrollment":22},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":"Metastatic Neuroendocrine Tumor","enrollment":94},{"nctId":"NCT07398859","phase":"PHASE2","title":"Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03-19","conditions":"Seasonal Allergic Rhinitis","enrollment":300},{"nctId":"NCT06400251","phase":"PHASE2","title":"Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-08","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT07498881","phase":"NA","title":"LasaiON is an Evidence-informed, Multimodal Self-regulation Program Designed to Reduce Emotional Distress and Strengthen Stress-regulation Skills by Combining Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) With Breathing Supported by Heart-rate Variability Biofeedback (HRV-B; emWave).","status":"NOT_YET_RECRUITING","sponsor":"University of the Basque Country (UPV/EHU)","startDate":"2026-03-30","conditions":"Adult","enrollment":200},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07498855","phase":"","title":"Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":"Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma","enrollment":11},{"nctId":"NCT02522611","phase":"PHASE1, PHASE2","title":"Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-02-27","conditions":"Intractable Pain, Palliative Care","enrollment":30},{"nctId":"NCT07498231","phase":"NA","title":"COronoary Microcirculation Analysis NETwork","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2025-10-10","conditions":"Coronary Artery Disease, Microcirculation Resistance, Microcirculation; Biomarkers; Myocardial Ischemia","enrollment":180},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT04439292","phase":"PHASE2","title":"Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT05638295","phase":"PHASE2","title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":105},{"nctId":"NCT07498803","phase":"PHASE2","title":"Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Philipps University Marburg","startDate":"2026-09-01","conditions":"Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH","enrollment":40},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT06630806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-10-30","conditions":"Plasma Cell Myeloma Refractory","enrollment":87},{"nctId":"NCT07493044","phase":"PHASE1","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","startDate":"2026-03-20","conditions":"Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT07241559","phase":"NA","title":"Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided 5% Dextrose Injection in Chronic Low Back Pain","status":"RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2025-11-01","conditions":"Chronic Low Back Pain","enrollment":75},{"nctId":"NCT07492108","phase":"NA","title":"Neuromodulation With Percutaneous Electrical Nerve Field Stimulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2026-01-08","conditions":"Gastroparesis Like Symptoms","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57287,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Entratinib","Cabotinib","Aletinib","Enmetrastuzumab","Trastuzumab"],"phase":"marketed","status":"active","brandName":"targeted therapy","genericName":"targeted therapy","companyName":"Fox Chase Cancer Center","companyId":"fox-chase-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Targeted therapy refers to drugs designed to attack specific molecular features of cancer cells, such as mutations or overexpressed proteins, while sparing normal cells. Used for Various solid tumors and hematologic malignancies (specific indications depend on the particular targeted agent).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}